Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nirmatrelvir + ritonavir - Pfizer

Drug Profile

Nirmatrelvir + ritonavir - Pfizer

Alternative Names: nirmatrelvir [PF-07321332] tablets and ritonavir tablets; Nirmatrelvir plus ritonavir - Pfizer; Nirmatrelvir+ritonavir - Pfizer; nirmatrelvir/ritonavir; PAXLOVID; PF 07321332 plus ritonavir - Pfizer; PF 07321332+ritonavir - Pfizer; PF-07321332/ritonavir

Latest Information Update: 07 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pfizer
  • Class Amides; Amines; Antivirals; Aza compounds; Carbamates; Fluorinated hydrocarbons; Heterocyclic bicyclo compounds; Nitriles; Pyrrolidinones; Small molecules; Thiazoles
  • Mechanism of Action Coronavirus-3C-like-proteinase inhibitors; HIV protease inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed COVID 2019 infections

Most Recent Events

  • 02 May 2024 Pfizer plans a phase I trial for COVID-19 infections (In Volunteers) in 2025 (PO,Tablet) (NCT06397144)
  • 24 Apr 2024 Pfizer reinitiates enrolment in a phase I trial for COVID-2019 infections (In adults) in USA (PO) (NCT05386472)
  • 03 Mar 2024 Efficacy and adverse events data from phase II trial in COVID-19 infections presented at the 31st Conference on Retroviruses and Opportunistic Infections 2024 (CROI-2024) (PO)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top